Overview
LTI-03 is a caveolin-1 Scaffolding Domain 7-Mer
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
Comprehensive Report on LTI-03: A Novel Peptide Therapeutic for Idiopathic Pulmonary Fibrosis
I. Introduction to LTI-03
A. Overview and Chemical Identity of LTI-03
LTI-03 is an investigational biotech product identified as a caveolin-1 Scaffolding Domain 7-Mer peptide.[1] This nomenclature reflects its origin and chemical nature. The compound is also known by several synonyms, including CSP-7 (Caveolin Scaffolding Domain Peptide 7-mer) and its specific amino acid sequence, PHE-THR-THR-PHE-THR-VAL-THR.[2] These alternative names are frequently used in scientific literature and company communications.
Key chemical and regulatory identifiers for LTI-03 are crucial for its precise identification and for tracking its development. These include:
- DrugBank ID: DB18491.[5] This accession number allows for standardized cross-referencing in the DrugBank database, a comprehensive resource for drug information.
- CAS Number: 1504575-10-3.[2] The Chemical Abstracts Service (CAS) registry number is a unique numerical identifier assigned to every chemical substance, ensuring unambiguous identification.
- FDA UNII (Unique Ingredient Identifier): JE7G34JYW4.[1] This identifier is utilized by the U.S. Food and Drug Administration (FDA) for substance registration and tracking.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/05/13 | Phase 2 | Active, not recruiting | |||
2023/07/20 | Phase 1 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.